Trial · NCT02020408
Monoamine Contributions to Neurocircuitry in Eating Disorders
NCT02020408, Phase 4, Completed, University of California, San Diego; results first posted 2020-04-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Monoamine Contributions to Neurocircuitry in Eating Disorders. Trials, record NCT02020408. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02020408
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Monoamine Contributions to Neurocircuitry in Eating Disorders
- NCT number
- NCT02020408
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 88 participants, actual
- Lead sponsor
- University of California, San Diego
- Conditions
- Eating Disorder
- Interventions
- [11C]raclopride, [11C]DASB, amphetamine
- First posted
- 2013-12-24
- Last updated
- 2020-04-27
- Results first posted
- 2020-04-27
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 5-HT Transporter Binding as Measured During the PET Scan | 90 minute PET scan | Use PET and \[11C\]DASB to explore 5-HTT receptor binding potential midbrain and striatal regions of interest in eating disorder subtypes. The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) -1. \[VT = distribution volume in tissue; VND = non-displaceable distribution volume\]. The binding of the 5-HTT on PET presumably reflects 5-HTT density and/or affinity. |
| Secondary | Dopamine D2/D3 Receptor Binding as Measured During the PET Scan After Amphetamine Administration | 90 min PET scan | Use PET and \[11C\]raclopride to explore Dopamine D2/D3 receptor binding potential (BPND) in striatal regions of interest in eating disorder subtypes after amphetamine administration. The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) -1. \[VT = distribution volume in tissue; VND = non-displaceable distribution volume\]. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 5-HT Transporter Binding as Measured During the PET Scan | 90 minute PET scan | binding potential (BPND) | MEAN | |
| SECONDARY | Dopamine D2/D3 Receptor Binding as Measured During the PET Scan After Amphetamine Administration | 90 min PET scan | Due to technical problems and temporary closure of the PET Facility during the study and consequent lack of time and funding for additional scanning, we were unable to recruit a sufficient number of women recovered from bulimia nervosa (BN) for the AMPHETAMINE CHALLENGE STUDY and therefore no data for this outcome measure were collected in REC BN. | binding potential (BPND) | MEAN |
Source ClinicalTrials.gov
Results by group39
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 5-HT Transporter Binding as Measured During the PET Scan | [11C]DASB Binding Potential Control Women | [11C]DASB BPND anteroventral striatum | 1.68 | Standard Deviation 0.26 | binding potential (BPND) |
| 5-HT Transporter Binding as Measured During the PET Scan | [11C]DASB Binding Potential in REC AN | [11C]DASB BPND anteroventral striatum | 1.54 | Standard Deviation 0.32 | binding potential (BPND) |
| 5-HT Transporter Binding as Measured During the PET Scan | [11C]DASB Binding Potential in REC ANBN | [11C]DASB BPND anteroventral striatum | 1.46 | Standard Deviation 0.47 | binding potential (BPND) |
| 5-HT Transporter Binding as Measured During the PET Scan | [11C]DASB Binding Potential in REC BN | [11C]DASB BPND anteroventral striatum | 1.60 | Standard Deviation 0.34 | binding potential (BPND) |
| 5-HT Transporter Binding as Measured During the PET Scan | [11C]DASB Binding Potential Control Women | [11C]DASB BPND post dorsal caudate | 0.44 | Standard Deviation 0.15 | binding potential (BPND) |
| 5-HT Transporter Binding as Measured During the PET Scan | [11C]DASB Binding Potential in REC AN | [11C]DASB BPND post dorsal caudate | 0.35 | Standard Deviation 0.18 | binding potential (BPND) |
| 5-HT Transporter Binding as Measured During the PET Scan | [11C]DASB Binding Potential in REC ANBN | [11C]DASB BPND post dorsal caudate | 0.39 | Standard Deviation 0.16 | binding potential (BPND) |
| 5-HT Transporter Binding as Measured During the PET Scan | [11C]DASB Binding Potential in REC BN | [11C]DASB BPND post dorsal caudate | 0.37 | Standard Deviation 0.19 | binding potential (BPND) |
| 5-HT Transporter Binding as Measured During the PET Scan | [11C]DASB Binding Potential Control Women | [11C]DASB BPND posterior putamen | 1.36 | Standard Deviation 0.25 | binding potential (BPND) |
| 5-HT Transporter Binding as Measured During the PET Scan | [11C]DASB Binding Potential in REC AN | [11C]DASB BPND posterior putamen | 1.27 | Standard Deviation 0.18 | binding potential (BPND) |
1 to 10 of 39Source ClinicalTrials.gov
See all 39 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | [11C]Raclopride, [11C]DASB, Amphetamine | 88 | |
| Overall Study | COMPLETED | [11C]Raclopride, [11C]DASB, Amphetamine | 85 | |
| Overall Study | NOT COMPLETED | [11C]Raclopride, [11C]DASB, Amphetamine | 3 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | High blood pressure | Cardiac disorders | [11C]Raclopride, [11C]DASB, Amphetamine | 2 | 85 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | [11C]Raclopride, [11C]DASB, Amphetamine | 0 | 85 |
| Total, other adverse events | [11C]Raclopride, [11C]DASB, Amphetamine | 2 | 85 |
| Total, serious adverse events | [11C]Raclopride, [11C]DASB, Amphetamine | 0 | 85 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01MH092793 | Monoamine Contributions to Neurocircuitry in Eating Disorders | KAYE, WALTER H; BAILER, URSULA FRANZISKA | UNIVERSITY OF CALIFORNIA, SAN DIEGO | NATIONAL INSTITUTE OF MENTAL HEALTH | 2011 to 2015 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02020408
GET https://conductscience.org/api/trials/v1/NCT02020408/results?page=2